ArticleAmerican journal of hematology2018

Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.

Susan O'Brien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.